World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
93658
World Ranking
2644
National Ranking
1479

Sagar Lonial publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Sagar Lonial sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,138 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Sagar Lonial D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Sagar Lonial sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 128 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Sagar Lonial is affiliated with Emory University in the United States and has a significant body of research primarily focused on hematology and oncology, with an emphasis on multiple myeloma. Their work spans the intersection of medicine, molecular biology, and genetics, reflecting expertise in both basic science and clinical research.

The scientist has contributed extensively to fields of study including:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

More specifically, their subfields of study encompass:

  • Hematology
  • Molecular Biology
  • Oncology
  • Immunology
  • Genetics

The main research topics covered by their publications are:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • CAR-T cell therapy research
  • Peptidase Inhibition and Analysis
  • Cancer Treatment and Pharmacology
  • Chronic Lymphocytic Leukemia Research
  • Ubiquitin and proteasome pathways

Sagar Lonial has a number of recent papers notable for their publication in high-impact journals. These include:

  • "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma," 2021, New England Journal of Medicine
  • "Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma," 2022, New England Journal of Medicine
  • "Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group," 2021, The Lancet Oncology
  • "Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial," 2020, The Lancet Oncology
  • "Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma," 2020, Journal of Clinical Oncology

Frequent collaborators in their research include:

  • Ajay K. Nooka
  • Jonathan L. Kaufman
  • Nisha S. Joseph
  • Craig C. Hofmeister
  • Madhav V. Dhodapkar

The venues where Sagar Lonial publishes most frequently are:

  • Clinical Lymphoma Myeloma & Leukemia
  • Blood
  • Journal of Clinical Oncology
  • Blood Cancer Journal
  • Transplantation and Cellular Therapy

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy

    Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Initial genome sequencing and analysis of multiple myeloma

    Michael A. Chapman;Michael S. Lawrence;Jonathan J. Keats;Kristian Cibulskis

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

    Donna M. Weber;Christine Chen;Ruben Niesvizky;Michael Wang

  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo

  • Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    S. Vincent Rajkumar;Jean Luc Harousseau;Brian Durie;Kenneth C. Anderson

  • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

    Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

    Richard I. Fisher;Steven H. Bernstein;Brad S. Kahl;Benjamin Djulbegovic

  • Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

    Taro Hitosugi;Sumin Kang;Matthew G. Vander Heiden;Tae Wook Chung

Frequent Co-Authors

Paul G. Richardson
Paul G. Richardson Harvard University
Lawrence H. Boise
Lawrence H. Boise Emory University
Christopher R. Flowers
Christopher R. Flowers The University of Texas MD Anderson Cancer Center
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Ravi Vij
Ravi Vij Washington University in St. Louis
David S. Siegel
David S. Siegel Hackensack University Medical Center
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Shaji Kumar
Shaji Kumar Mayo Clinic
Saad Z. Usmani
Saad Z. Usmani Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA often opens the door to diverse healthcare career options beyond the traditional MD path. For those eager to enter patient care quickly, a 6 month lpn program online offers a fast-track way to become a Licensed Practical Nurse. This pathway provides hands-on experience and foundational clinical skills.

Nurses with advanced degrees may consider mental health specialties. The shortest post master's pmhnp online programs enable registered nurses to quickly qualify as Psychiatric Mental Health Nurse Practitioners, responding to the growing demand for mental health professionals.

Not all healthcare careers require direct patient care. Students interested in the business and leadership side of medicine can explore healthcare administration degrees that prepare graduates for roles in hospital management and healthcare services.

For those pursuing senior leadership, affordable mha online programs provide the skills needed to oversee complex healthcare organizations, all through flexible online study. These programs make advancing your career more accessible and align with the evolving landscape of U.S. healthcare.

Best Scientists Citing Sagar Lonial

Trending Scientists

Recently Published Articles